HAEM5:Erdheim-Chester disease: Difference between revisions
| [checked revision] | [pending revision] |
Bailey.Glen (talk | contribs) No edit summary |
mNo edit summary |
||
| Line 1: | Line 1: | ||
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]] | [[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]] | ||
| Line 8: | Line 7: | ||
==Primary Author(s)*== | ==Primary Author(s)*== | ||
Mayuri Shende, MBBS, DCP, FCPS, DNB, ASCP-SH CM | |||
Scott Turner, PhD<span style="color:#0070C0"> (''<span class="blue-text">EXAMPLE:</span>'' Jane Smith, PhD) </span> | |||
__TOC__ | __TOC__ | ||
| Line 36: | Line 37: | ||
==Definition / Description of Disease== | ==Definition / Description of Disease== | ||
Erdheim–Chester disease (ECD) is a histiocytic neoplasm characterized by accumulation of mature histiocytes, associated with inflammation and fibrosis in many different organs . <span style="color:#0070C0">(''Instructions: Brief description of approximately one paragraph - include disease context relative to other WHO classification categories, diagnostic criteria if applicable, and differential diagnosis if applicable. Other classifications can be referenced for comparison.'') </span> | |||
==Synonyms / Terminology== | ==Synonyms / Terminology== | ||
Erdheim–Chester disease (ECD) <span style="color:#0070C0">(''Instructions: Include currently used terms and major historical ones, adding “(historical)” after the latter.'') </span> | |||
==Epidemiology / Prevalence== | ==Epidemiology / Prevalence== | ||
Rare histiocytic neoplasm with median age at diagnosis being 55 years, male predilection. Many cases might be underdiagnosed. | |||
==Clinical Features== | ==Clinical Features== | ||
| Line 51: | Line 52: | ||
{| class="wikitable" | {| class="wikitable" | ||
|'''Signs and Symptoms''' | |'''Signs and Symptoms''' | ||
| | |Asymptomatic or presents with fever, fatigue | ||
Site related symptoms like bone pain, exophthalmos, xanthelasma, diabetes insipidus | |||
CNS-mass effect or neurodegerative type symptoms | |||
Cardiac tamponade | |||
Painful abdominal mass | |||
|- | |- | ||
|'''Laboratory Findings''' | |'''Laboratory and imaging Findings''' | ||
| | |Symmetrical osteosclerosis of the leg bones on PET with bilateral uptake of FDG | ||
Hairy-kidney appearance in cases of bilateral perinephric involvement | |||
Mass-like infiltration of the right atrium on MRI | |||
Sclerosis of sinuses of the face on CT | |||
May be associated with chronic myelomonocytic leukaemia, Langerhans cell histiocytosis | |||
|} | |} | ||
==Sites of Involvement== | ==Sites of Involvement== | ||
ECD can involve any organ, mostly excludes lymph nodes, spleen and liver. In majority of cases (80-95%) involves long bones, bilaterally and symmetric. Perinephric, periaortic involvement also frequent. Pitutary, neurologic, pulmonary, cardiac, serosal and cutaneous involvement (manifesting as xanthelasma or papule) also noted. <span style="color:#0070C0">(''Instruction: Indicate physical sites; <span class="blue-text">EXAMPLE:</span> nodal, extranodal, bone marrow'') </span> | |||
==Morphologic Features== | ==Morphologic Features== | ||
Histopathology: | |||
*Infiltration by foamy, lipid-laden, and/or small mononuclear histiocytes and variable proportions of Touton giant cells, small lymphocytes, plasma cells, and/or neutrophils. | |||
*Fibrosis usually present | |||
*Can be misdiagnosed as reactive fibroinflammatory process if there is extensive fibrosis or it may also show partial morphological and immunophenotypic overlap with Rosai–Dorfman disease or with reticulohistiocytosis or Langerhans cell histiocytosis. | |||
==Immunophenotype== | ==Immunophenotype== | ||
| Line 81: | Line 92: | ||
!Finding!!Marker | !Finding!!Marker | ||
|- | |- | ||
|Positive (universal)|| | |Positive (universal)||CD163, CD68, CD14, and CD4 | ||
Positive for factor XIIIa, fascin, and (less commonly) S100 | |||
Diffuse strong cytoplasmic staining with VE1 monoclonal antibody suggestive of BRAF p.V600E mutation, but should be confirmed with molecular analysis | |||
Expression of phosphorylated ERK also noted frequently | |||
|- | |- | ||
|Positive (subset)||<span class="blue-text">EXAMPLE:</span> CD2 | |Positive (subset)||<span class="blue-text">EXAMPLE:</span> CD2 | ||
|- | |- | ||
|Negative (universal)|| | |Negative (universal)||CD1a and CD207 | ||
|- | |- | ||
|Negative (subset)||<span class="blue-text">EXAMPLE:</span> CD4 | |Negative (subset)||<span class="blue-text">EXAMPLE:</span> CD4 | ||
| Line 224: | Line 240: | ||
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome | !Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome | ||
|- | |- | ||
| | |Gain-of-function somatic alteration | ||
| | |MAPK cell signalling pathway | ||
|<span class="blue-text">EXAMPLE:</span> Increased cell growth and proliferation | |<span class="blue-text">EXAMPLE:</span> Increased cell growth and proliferation | ||
|- | |- | ||
| | |''BRAF'' p.V600E mutations or ''BRAF'', ''ARAF'', ''NRAS'', ''KRAS'', or ''MAP2K1'' | ||
|<span class="blue-text">EXAMPLE:</span> Cell cycle regulation | |<span class="blue-text">EXAMPLE:</span> Cell cycle regulation | ||
|<span class="blue-text">EXAMPLE:</span> Unregulated cell division | |<span class="blue-text">EXAMPLE:</span> Unregulated cell division | ||
|- | |- | ||
| | | | ||
| | |''PIK3CA'' | ||
|<span class="blue-text">EXAMPLE:</span> Abnormal gene expression program | |<span class="blue-text">EXAMPLE:</span> Abnormal gene expression program | ||
|} | |} | ||
| Line 257: | Line 273: | ||
'''EXAMPLE Book''' | '''EXAMPLE Book''' | ||
# | #John Chan, et al., Erdheim–Chester disease in WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer; 2024. . (WHO classification of tumours series, 5th ed.; vol. 11). <nowiki>https://publications.iarc.who.int/637</nowiki>. | ||
==Notes== | ==Notes== | ||
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome. | <nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome. | ||
<nowiki>*</nowiki>''Citation of this Page'': “Erdheim-Chester disease”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Erdheim-Chester_disease</nowiki>. | <nowiki>*</nowiki>''Citation of this Page'': “Erdheim-Chester disease”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Erdheim-Chester_disease</nowiki>. | ||
[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases E]] | [[Category:HAEM5]] | ||
[[Category:DISEASE]] | |||
[[Category:Diseases E]] | |||